In vivo deamidation characterization of monoclonal antibody by LC/MS/MS.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Analytical Chemistry

• Publication date

  2005-01-22

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/AC0494174PMID 15732928
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Deamidation of the asparaginyl-glycyl sequence.

  2009cited by this paper
• Degradation of growth hormone releasing factor analogs in neutral aqueous solution is related to deamidation of asparagine residues. Replacement of asparagine residues by serine stabilizes.

  2009cited by this paper
• The effects of alpha‐helix on the stability of Asn residues: Deamidation rates in peptides of varying helicity

  2008cited by this paper
• Deamidations in Recombinant Human Phenylalanine Hydroxylase

  2003cited by this paper
• Monoclonal antibodies as therapeutics in oncology.

  2002cited by this paper
• Monoclonal antibodies in immune and inflammatory diseases.

  2002cited by this paper
• Deamidation of human proteins

  2001cited by this paper
• Age-dependent deamidation of asparagine residues in proteins.

  2001cited by this paper
• Characterization of human lens major intrinsic protein structure.

  2000cited by this paper
• Spontaneous deamidation and isomerization of Asn108 in prion peptide 106-126 and in full-length prion protein.

  1999cited by this paper
• Deamidation and Isoaspartate Formation in Smeared Tau in Paired Helical Filaments

  1999cited by this paper
• Age-dependent deamidation of H1° histones in chromatin of mammalian tissues

  1999cited by this paper
• A conserved deamidation site at asn 2 in the catalytic subunit of mammalian cAMP‐dependent protein kinase detected by capillary LC‐MS and tandem mass spectrometry

  1998cited by this paper
• Deamidation of asparagine and glutamine residues in proteins and peptides: structural determinants and analytical methodology.

  1994cited by this paper
• Spontaneous degradation of polypeptides at aspartyl and asparaginyl residues: Effects of the solvent dielectric

  1993cited by this paper
• Age-dependent deamidation of alpha B-crystallin.

  1993cited by this paper
• Analysis of recombinant proteins by isoelectric focusing in immobilized pH gradients

  1992cited by this paper
• Capillary electrophoresis-electrospray mass spectrometry for the analysis of recombinant bovine and porcine somatotropins.

  1992cited by this paper
• Optimal conditions for the use of protein L-isoaspartyl methyltransferase in assessing the isoaspartate content of peptides and proteins.

  1991cited by this paper
• Distribution of glutamine and asparagine residues and their near neighbors in peptides and proteins.

  1991cited by this paper
• Isolation and characterization of a succinimide variant of methionyl human growth hormone.

  1991cited by this paper
• Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation.

  1987cited by this paper
• Stoichiometric methylation of porcine adrenocorticotropin by protein carboxyl methyltransferase requires deamidation of asparagine 25. Evidence for methylation at the alpha-carboxyl group of atypical L-isoaspartyl residues.

  1984cited by this paper

• Near UV and Visible Light-Induced Degradation of IgG2: Photo-Fenton Reaction in Citrate Buffer.

  2026cites this paper
• In vivo analysis techniques for antibody drug: Recent advances and methodological insights

  2025cites this paper
• In vitro Stability Study of a Panel of Commercial Antibodies at Physiological pH and Temperature as a Guide to Screen Biologic Candidate Molecules for the Potential Risk of In vivo Asparagine Deamidation and Activity Loss

  2025cites this paper
• Genetic Factors Affecting the Quality of Recombinant Therapeutic Proteins in CHO Cells.

  2025cites this paper
• Revealing Unpredicted Aspartic Acid Isomerization Hotspots by Probing Diagnostic Fragmentation Propensities in Top-Down and Middle-Down Mass Spectrometry.

  2025cites this paper
• Data-Driven Analysis of Monoclonal Antibody Charge Variants in Perfusion Cultures

  2025cites this paper
• Calcium-dependent magnetic separation: A novel approach for the integrated processing of high-quality mAbs

  2025cites this paper
• Chemical Mobilization-Based Capillary Isoelectric Focusing-Mass Spectrometry Using the nanoCEasy Interface for Pharmaceutical Protein Analysis.

  2024cites this paper
• Countercurrent preferential precipitation of acidic variants from monoclonal antibody pools

  2024cites this paper
• Mapping conformational changes on bispecific antigen-binding biotherapeutic by covalent labeling and mass spectrometry

  2024cites this paper
• Comparative study of trastuzumab modification analysis using mono/multi-epitope affinity technology with LC-QTOF-MS

  2024cites this paper
• A thermodynamic investigation into protein–excipient interactions involving different grades of polysorbate 20 and 80

  2024cites this paper
• A thermosensitive hydrogel for the sustained delivery of exosomes extracted from menstrual blood mesenchymal stem cells and frizzled antibody on triple-negative breast cancer cells in vitro

  2024cites this paper
• A robust and validated LC-MS/MS method for the quantification of ramucirumab in rat and human serum using direct enzymatic digestion without immunoassay.

  2024cites this paper
• Utilization of Liquid Chromatography-Mass Spectrometry and High-Resolution Ion Mobility-Mass Spectrometry to Characterize Therapeutically Relevant Peptides with Asparagine Deamidation and Isoaspartate.

  2024cites this paper
• Deamidation analysis of therapeutic drugs using matrix-assisted laser desorption ionization mass spectrometry and a novel algorithm QuanDA.

  2024cites this paper
• Multiepitope recognition technology promotes the in-depth analysis of antibody‒drug conjugates

  2024cites this paper
• LAP: Liability Antibody Profiler by sequence & structural mapping of natural and therapeutic antibodies

  2024cites this paper
• Comparative stability study and aggregate analysis of Bevacizumab marketed formulations using advanced analytical techniques

  2023cites this paper
• Tutorial review for peptide assays: An ounce of pre-analytics is worth a pound of cure.

  2023cites this paper
• Post-translational modifications comparative identification and kinetic study of infliximab innovator and biosimilars in serum using capillary electrophoresis-tandem mass spectrometry.

  2023cites this paper
• Mimotope peptide modified pompon mum-like magnetic microparticles for precise recognition, capture and biotransformation analysis of rituximab in biological fluids

  2023cites this paper
• Discovery and Control of Succinimide Formation and Accumulation at Aspartic Acid Residues in The Complementarity-Determining Region of a Therapeutic Monoclonal Antibody

  2023cites this paper
• Trastuzumab Charge Variants: a Study on Physicochemical and Pharmacokinetic Properties

  2023cites this paper
• Comprehensive perspective towards the management of proteinopathies by elucidating protein misfolding and aggregation.

  2023cites this paper
• Multiplex Bioanalytical Methods for Comprehensive Characterization and Quantification of the Unique Complementarity-Determining-Region Deamidation of MEDI7247, an Anti-ASCT2 Pyrrolobenzodiazepine Antibody–Drug Conjugate

  2023cites this paper
• Simultaneous quantification and structural characterization of monoclonal antibodies after administration using capillary zone electrophoresis-tandem mass spectrometry.

  2023cites this paper
• Bioprocess Challenges in Purification of Therapeutic Protein Charge Variants

  2023cites this paper
• Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics

  2022cites this paper
• Protein Stability After Administration: A Physiologic Consideration.

  2022cites this paper
• Multiattribute Monitoring of Charge-Based Heterogeneity of Recombinant Monoclonal Antibodies Using 2D HIC-WCX-MS.

  2022cites this paper
• Antibody charge variant modulation by in vitro enzymatic treatment in different Chinese hamster ovary cell cultures

  2022cites this paper
• Development and optimization of a LC-MS based multi-attribute method (MAM) workflow for characterization of therapeutic Fc-fusion protein.

  2022cites this paper
• In vitro/in vivo degradation analysis of trastuzumab by combining specific capture on HER2 mimotope peptide modified material and LC-QTOF-MS.

  2022cites this paper
• Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants

  2022cites this paper
• Identification, Efficacy, and Stability Evaluation of Succinimide Modification With a High Abundance in the Framework Region of Golimumab

  2022cites this paper
• Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab

  2022cites this paper
• Design and optimization of membrane chromatography for monoclonal antibody charge variant separation

  2022cites this paper
• Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.

  2022cites this paper
• Micro-Heterogeneity of Antibody Molecules.

  2021cites this paper
• Lectin and Liquid Chromatography-Based Methods for Immunoglobulin (G) Glycosylation Analysis.

  2021cites this paper
• Optimization of therapeutic antibodies

  2021cites this paper
• Change of charge variant composition of trastuzumab upon stressing at physiological conditions.

  2021cites this paper
• Enrichment and Liquid Chromatography–Mass Spectrometry Analysis of Trastuzumab and Pertuzumab Using Affimer Reagents

  2021cites this paper
• Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.

  2021cites this paper
• Inter-laboratory study to evaluate the performance of automated online characterization of antibody charge variants by multi-dimensional LC-MS/MS.

  2021cites this paper
• DMTMM-Mediated Intramolecular Cyclization of Acidic Residues in Peptides/Proteins

  2021cites this paper
• Similarity assessment of charge variants for bevacizumab biosimilar formulations using imaged capillary isoelectric focusing

  2021cites this paper
• Productivity improvement and charge variant modulation for intensified cell culture processes by adding a carboxypeptidase B (CpB) treatment step

  2021cites this paper
• Mass Spectrometry-Based Methods for Immunoglobulin G N-Glycosylation Analysis.

  2021cites this paper
• Analytical Challenges Assessing Protein Aggregation and Fragmentation Under Physiologic Conditions.

  2021cites this paper
• Analytical tools for the characterization of deamidation in monoclonal antibodies

  2021cites this paper
• A novel twin‐column continuous chromatography approach for separation and enrichment of monoclonal antibody charge variants

  2021cites this paper
• Structure and Functional Characterization of a Humanized Anti-CCL20 Antibody following Exposure to Serum Reveals the Formation of Immune Complex That Leads to Toxicity

  2021cites this paper
• Introducing protein deamidation: landmark discoveries, societal outreach, and tentative priming workflow to address deamidation.

  2021cites this paper
• Mass spectrometric analysis of protein deamidation - a focus on top-down and middle-down mass spectrometry.

  2020cites this paper
• Tracking the physical stability of fluorescent-labeled mAbs under physiologic invitro conditions in human serum and PBS.

  2020cites this paper
• Establishment of a highly precise multi-attribute method for the characterization and quality control of therapeutic monoclonal antibodies

  2020cites this paper
• In Vivo Stability of Therapeutic Proteins

  2020cites this paper
• Chapter 1: Monoclonal Antibodies: Structure, Physicochemical Stability, and Protein Engineering

  2020cites this paper
• Separation of monoclonal antibody charge variants using cation exchange chromatography: Resins and separation conditions optimization

  2020cites this paper
• Multiple-parallel-protease digestion coupled with high-resolution mass spectrometry: An approach towards comprehensive peptide mapping of therapeutic mAbs.

  2020cites this paper
• Characterization of Asparagine Deamidation in Immunodominant Myelin Oligodendrocyte Glycoprotein Peptide Potential Immunotherapy for the Treatment of Multiple Sclerosis

  2020cites this paper
• A Tiered Approach for Characterization to Ensure Quality, Reproducibility, and Long-Term Stability of Critical Reagents in Regulated Bioanalysis to Support PK/ADA/NAb Assays for Biologics and Vaccines Programs.

  2020cites this paper
• All ion differential analysis refines the detection of terminal and internal diagnostic fragment ions for the characterization of biologics product-related variants and impurities by middle-down mass spectrometry.

  2019cites this paper
• Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides

  2019cites this paper
• Deamidation of Proteins

  2019cites this paper
• Engineering an anti-CD52 antibody for enhanced deamidation stability

  2019cites this paper
• Biosimilarity assessment of biopharmaceuticals for quality control

  2019cites this paper
• Machine Learning Enables Accurate Prediction of Asparagine Deamidation Probability and Rate

  2019cites this paper
• Structural and biochemical basis of the formation of isoaspartate in the complementarity-determining region of antibody 64M-5 Fab

  2019cites this paper
• Modifications of recombinant monoclonal antibodies in vivo.

  2019cites this paper
• Susceptibility of protein therapeutics to spontaneous chemical modifications by oxidation, cyclization, and elimination reactions

  2019cites this paper
• Product-Related Factors and Immunogenicity of Biotherapeutics

  2019cites this paper
• An Automated and Qualified Platform Method for Site-Specific Succinimide and Deamidation Quantitation Using Low-pH Peptide Mapping.

  2019cites this paper
• Structure, heterogeneity and developability assessment of therapeutic antibodies

  2019cites this paper
• Crystal structure of anti-GLD52 Fab complex with human GLD52 peptide mimetic

  2019cites this paper
• Analysis of four therapeutic monoclonal antibodies by online capillary isoelectric focusing directly coupled to quadrupole time‐of‐flight mass spectrometry

  2019cites this paper
• Ionisation bias undermines the use of matrix‐assisted laser desorption/ionisation for estimating peptide deamidation: Synthetic peptide studies demonstrate electrospray ionisation gives more reliable response ratios

  2019cites this paper
• A generic method for intact and subunit level characterization of mAb charge variants by native mass spectrometry.

  2019cites this paper
• Towards The Development of Biobetter Therapeutic Whole Antibodies

  2019cites this paper
• Special Section on Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities — Minireview Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides

  2019cites this paper
• Modulating cell culture oxidative stress reduces protein glycation and acidic charge variant formation

  2019cites this paper
• Utility of High Resolution NMR Methods to Probe the Impact of Chemical Modifications on Higher Order Structure of Monoclonal Antibodies in Relation to Antigen Binding

  2019cites this paper
• Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters

  2019cites this paper
• Shedding light into the subcutis - A mass spec based immunocapture assay enables full characterization of therapeutic antibodies after injection in-vivo.

  2019cites this paper
• Quantitation and modeling of post-translational modifications in a therapeutic monoclonal antibody from single- and multiple-dose monkey pharmacokinetic studies using mass spectrometry

  2019cites this paper
• Macro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies

  2019influential citation
• Industrial bioprocessing perspectives on managing therapeutic protein charge variant profiles

  2018cites this paper
• The importance of handling high-value biologicals: Physico-chemical instability and immunogenicity of monoclonal antibodies.

  2018cites this paper
• Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?

  2018cites this paper
• Microheterogeneity of Recombinant Antibodies: Analytics and Functional Impact

  2018cites this paper
• Analytical comparability study of recombinant monoclonal antibody therapeutics

  2018cites this paper
• Screening and development of natural compounds as tools to improve IgG production and quality in recombinant CHO cell culture

  2018cites this paper
• Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7

  2018cites this paper
• Challenges related to the immunogenicity of parenteral recombinant proteins: Underlying mechanisms and new approaches to overcome it

  2018cites this paper
• High Resolution Capillary Isoelectric Focusing Mass Spectrometry Analysis of Peptides, Proteins, And Monoclonal Antibodies with a Flow-through Microvial Interface.

  2018cites this paper
• Structure Based Prediction of Asparagine Deamidation Propensity in Monoclonal Antibodies

  2018cites this paper
• Asparagine Deamidation in a Complementarity Determining Region of a Recombinant Monoclonal Antibody in Complex with Antigen.

  2018cites this paper
• Use of In Vitro Systems To Model In Vivo Degradation of Therapeutic Monoclonal Antibodies.

  2018cites this paper